PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

Stock Information for PreveCeutical Medical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PreveCeutical Medical Inc.

PREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM
New to The Street Announces its Five Corporate Interviews, airings on Newsmax and FOX Business Network
PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application
PreveCeutical Showcases Dynamic Evolution in AI Strategy
PreveCeutical Engages New to the Street for Production & Broadcasting Services
PreveCeutical Files Cyclic Peptides And Uses Thereof in the EU and Australia
PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof
PreveCeutical Medical - Sol-Gel and Uses thereof Patent Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.